Recommendations for the appropriate management of diabetic macular edema: Light on DME survey and consensus document by an expert panel

European Journal of Ophthalmology

Volumn 26, Issue 3, 2016, Pages 252-261

  Bandello, Francesco ^a   Midena, Edoardo ^b   Menchini, Ugo ^c   Lanzetta, Paolo ^d,e  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e Istituto Europeo di Microchirurgia Oculare   (Italy)

Author keywords

Anti VEGF; Diabetic macular edema; Diabetic retinopathy; Intravitreal injection; Ranibizumab

Indexed keywords

CORTICOSTEROID; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL PRACTICE; CONSENSUS; DELPHI STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG TREATMENT FAILURE; GLYCEMIC INDEX; HEALTH CARE SURVEY; HUMAN; LOW LEVEL LASER THERAPY; NORMAL HUMAN; OPHTHALMOLOGIST; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; RETINA FLUORESCEIN ANGIOGRAPHY; ANTAGONISTS AND INHIBITORS; CONSENSUS DEVELOPMENT; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; MACULAR EDEMA; PHYSIOLOGY; PRACTICE GUIDELINE; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; SURVEYS AND QUESTIONNAIRES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84963819000     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000736     Document Type: Article

References (43)

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136.
2. Yau JWY, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3): 556-564.
3. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII: the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859-1868.
4. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497-503.
5. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology. 1994;101(6):1061-1070.
6. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1805.
7. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology. 1987; 94(7):761-774.
8. The Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines 2012. Available at: http://www.icoph.org/dynamic/attachments/taskforce:documents/2012-sci-267_diabetic_retinopathy_guidelines_december_2012.pdf. Accessed March 5, 2015.
9. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
10. Dowler JG. Laser management of diabetic retinopathy. J R Soc Med. 2003;96(6):277-279.
11. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22): 1480-1487.
12. Bandello F, Cunha-Vaz J, Chong NV, et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye. 2012;26(4):485-493.
13. Bandello F, Casalino G, Loewenstein A, Goldstein M, Pelayes D, Battaglia Parodi M. Pharmacological approach to diabetic macular edema. Ophthalmic Res. 2014;51(2):88-95.
14. Stewart MW. Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep. 2014;14(8):510.
15. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405.
16. Nguyen QD, Shah SM, Khwaja AA, et al; READ-2 Study Group. Two-year outcomes of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study [erratum 2011;118:1016]. Ophthalmology. 2010;117(11):2146-2151.
17. Elman MJ, Bressler NM, Qin H, et al; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609-614.
18. Elman MJ, Qin H, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012; 119(11):2312-2318.
19. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
20. Do DV, Nguyen QD, Khwaja AA, et al; READ-2 Study Group. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013;131(2):139-145.
21. Mitchell P, Bressler N, Tolley K, et al; RESTORE Study Group. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmol. 2013;131(10):1339-1347.
22. Schmidt-Erfurth U, Lang GE, Holz FG, et al; RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5): 1045-1053.
23. Brown DM, Nguyen QD, Marcus DM, et al; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022.
24. Wilson JGM, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization, 1968. Available at: http://apps.who.int/iris/handle/10665/37650. Accessed December 26, 2015.
25. Echouffo-Tcheugui JB, Ali MK, Roglic G, Hayward RA, Narayan KM. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. Diabet Med. 2013;30(11):1272-1292.
26. Bäcklund LB, Algvere PV, Rosenqvist U. New blindness in diabetes reduced by more than one-third in Stockholm County. Diabet Med. 1997;14(9):732-740.
27. Arun CS, Al-Bermani A, Stannard K, Taylor R. Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age population. Diabet Med. 2009;26(5):489-492.
28. Arora S, Kolb S, Goyder E, McKibbin MM. Trends in the incidence of visual impairment resulting from diabetic retinopathy in the Leeds metropolitan area, 2005-2010. Diabet Med. 2012;29(7):e112-e116.
29. Hautala N, Aikkila R, Korpelainen J, et al. Marked reductions in visual impairment due to diabetic retinopathy achieved by efficient screening and timely treatment. Acta Ophthalmol. 2014;92(6):582-587.
30. Bressler NM, Varma R, Doan QV, et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(2):168-173.
31. Trento M, Bajardi M, Borgo E, et al. Perceptions of diabetic retinopathy and screening procedures among diabetic people. Diabet Med. 2002;19(10):810-813.
32. Linee-guida per lo screening, la diagnostica e il trattamento della retinopatia diabetica in Italia. Revisione e aggiornamento 2013 a cura del Gruppo di Lavoro sulle Complicanze Oculari del Diabete della Società Italiana di Diabetologia. Available at: http://www.aemmedi.it/files/Lineeguida_Raccomandazioni/2002/2002-screening-diagnosticatrattamento-retinopatia-diabetica.pdf. Accessed June 4, 2015.
33. Panozzo G, Parolini B, Gusson E, et al. Diabetic macular edema: an OCT-based classification. Semin Ophthalmol. 2004;19 (12):13-20.
34. Want A, Rewbury R, Varughese R, Chong V. Classification of diabetic macular edema based on the morphology in optical coherent topography. Poster presented at the annual meeting of the Association for Research in Vision and Ophthalmology; Orlando, FL, USA; May 4-8, 2014. Available at: http://www.arvo.org/webs/am2014/abstract/sessions/345.pdf. Accessed June 4, 2015.
35. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med. 1993;329(14): 977-986.
36. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-389.
37. Kiire CA, Porta M, Chong V. Medical management for the prevention and treatment of diabetic macular edema. Surv Ophthalmol. 2013;58(5):459-465.
38. Matsuda S, Tam T, Singh RP, et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications. 2014;28(2): 166-170.
39. Ranibizumab for treating diabetic macular oedema. NICE technology appraisal guidance 274. April 2013. Available at: https://www.nice.org.uk/guidance/ta274. Accessed December 26, 2015.
40. Lucentis® (ranibizumab) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000715/WC500043546.pdf. Accessed June 4, 2015.
41. Pruente C, Group RS. Efficacy and safety of ranibizumab in two treat-and-extend versus pro-re-nata regimes in patients with visual impairment due to diabetic macular edema: 24-month results of RETAIN study. Invest Ophthalmol Vis Sci. 2014;55: E-Abstract 1700.
42. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97(4):454-459.
43. Wells JA, Glassman AR, Ayala AR, et al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13):1193-1203.